Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study
ConditionSurgical Site Infection
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMonash University
About this trial
This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery
Eligibility criteria
Qualifiers
None
Disqualifiers
Age <18 years
American Society of Anesthesiology (ASA) 5
Subjects with GFR <40mL/min/1.73m2 or those requiring continuous renal replacement therapy, haemodialysis or peritoneal dialysis
Surgery for suspected or proven endocarditis or deep sternal wound infection
Trial design
Treatments tested in this trial
- Cefazolin
- Water for injection
Treatment groups
9,180 Participants
are divided into 3 treatment groupsSponsors and collaborators
Monash University
Lead sponsor
ANZCA CTN
Collaborator
Source ClinicalTrials.gov